Order results by:
| Issue | Title | |
| Vol 18, No 3 (2025) | Modeling the efficiency of chronic hepatitis С treatment | Abstract similar documents |
| V. V. Omelyanovskiy, V. P. Chulanov, N. N. Pimenov, E. I. Rumiantseva, F. V. Gorkavenko, K. I. Matrenin, S. I. Zinadinov | ||
| "... (CHC) at the national level. Material and methods. A Markov model was used to predict the direct ..." | ||
| Vol 12, No 2 (2019) | Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers | Abstract similar documents |
| E. V. Radchenko, A. S. Kolbin | ||
| "... disability) was 510.6 billion rubles. The difference between the smokers and the equal-sized non-smoking ..." | ||
| Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
| E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
| "... .18 billion rubles (with government funding) to 318.14 billion rubles. Concurrently, pharmacocorrection ..." | ||
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| "... social-economic burden of SMA in Russia was 2.37 billion RUR/year (2.38 million RUR/patient/year ..." | ||
| Vol 18, No 1 (2025) | Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia | Abstract similar documents |
| A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova | ||
| "... and pembrolizumab biosimilars, resulting in savings of 15.1 and 3.8 billion rubles, respectively. In the group ..." | ||
| Vol 14, No 4 (2021) | Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy | Abstract similar documents |
| N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev | ||
| "... in Russia. Centralizing procurements at the expense of federal budget may save up to 20.7% or 1.8 billion ..." | ||
| Vol 16, No 4 (2023) | Socio-economic burden of respiratory syncytial viral infection of the lower respiratory tract in children aged from birth to 5 years in the Russian Federation: modeling results | Abstract similar documents |
| V. I. Ignatyeva, D. Yu. Ovsyannikov, A. E. Tsygankov, E. E. Yagnenkova, V. R. Amirova, M. M. Maryanyan, A. S. Mokrova | ||
| "... . Medical costs for treatment exceed 2.2 billion rubles, and the damage to GDP as a result of lethal ..." | ||
| Vol 15, No 3 (2022) | Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... practice, the budget costs for pharmacotherapy of patients with DM2+DN were 99.82 billion rubles ..." | ||
| Vol 18, No 3 (2025) | Pharmacoepidemiology of anxiolytics in the Russian Federation | Abstract similar documents |
| Yu. M. Gomon, A. S. Kolbin, V. A. Lavrova, N. G. Neznanov, D. N. Nuriakhmitova | ||
| "... ranked first in terms of acquisition costs, amounting to 2.1 billion rubles in 2019 and 3.2 billion ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov | ||
| "... ,7 billion rubles (500 million rubles less than for second best option), and government reimbursement costs ..." | ||
| Vol 8, No 4 (2015) | HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS | Abstract similar documents |
| N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova | ||
| "... healthcare spending inefficient, which equals to real 269-435 billion rubles of inefficient spending annually. ..." | ||
| Vol 8, No 4 (2015) | PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER | Abstract similar documents |
| D. A. Zhukov | ||
| "... .9 billion rubles (42.2 million EUR). According to the generated modelling, the pneumococcal (PPSV23 ..." | ||
| Vol 16, No 4 (2023) | Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation | Abstract similar documents |
| M. V. Zhuravleva, K. A. Kokushkin, E. A. Luchinin, E. V. Luchinina, T. R. Kameneva, E. V. Kuznetsova, V. S. Krysanova, E. V. Makarova, L. G. Zhukova | ||
| "... empegfilgrastim will result in a cost reduction of 9.4 billion rubles per 1 year compared to filgrastim ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| "... России, составит 2,838 млрд руб., 2,608 млрд руб. и 2,283 млрд руб. для монотерапии ЛС Эпртаког альфа ..." | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... Federation, this will save 17.2 billion rubles a year. Conclusion. The results obtained showed that, despite ..." | ||
| Vol 18, No 1 (2025) | The sale of medicines used for diabetes mellitus treatment in retail segment of Russian pharmaceutical market | Abstract similar documents |
| I. K. Petrukhina, A. M. Lazarev, T. K. Ryazanova, P. A. Lebedev, E. P. Gladunova, G. T. Glembotskaya | ||
| "... , 54.9 million packages of antidiabetic drugs were sold for 32.4 billion rubles from 2020 to 2023 ..." | ||
| Vol 16, No 2 (2023) | Improving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025 | Abstract similar documents |
| V. V. Omelyanovskiy, I. A. Zheleznyakova, A. V. Zuev, O. S. Plakhotnik, O. A. Volkova, L. M. Davydova, G. V. Trifonova, E. V. Semakova, E. A. Prokhorovich, A. S. Volkova | ||
| "... вирусного гепатита С (ХВГС) у взрослых, в которых отсутствуют интерфероновые схемы лекарственной терапии ..." | ||
| Vol 15, No 2 (2022) | Improving the efficiency of the medicine provision system for patients with malignant neoplasms | Abstract similar documents |
| Yu. A. Agafonova, D. V. Fedyaev, A. V. Snegovoy, V. V. Omelyanovskiy | ||
| "... budget expenditures in the amount of 62.5 billion rubles or 2.65% of the total costs of the State ..." | ||
| Vol 16, No 4 (2023) | Sales of antitumor drugs in the retail segment of the Russian pharmaceutical market | Abstract similar documents |
| I. K. Petrukhina, T. K. Ryazanova, E. P. Gladunova, A. M. Lazarev, A. A. Krivova | ||
| "... .5 billion rubles were purchased at the expense of citizens’ personal funds, i.e. approximately 1/6 ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... фармакотерапию 24 редких заболеваний составили 15,73 млрд руб. в год (6,36 млрд руб. на детей и 9,37 млрд руб. на ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation | Abstract similar documents |
| A. Yu. Kulikov, L. A. Komarov | ||
| "... церебролизина для лечения ОНМК по ишемическому типу позволяет сэкономить примерно 1,47 млрд руб. в год в расчете ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... дешевой альтернативой, позволяющей снизить стоимость годового лечения одного пациента на 2,68 млн руб ..." | ||
| Vol 10, No 1 (2017) | PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM | Abstract similar documents |
| N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova | ||
| "... 4-7 млрд руб.) ежегодно до2020 г. ..." | ||
| Vol 14, No 4 (2021) | Economic burden of chronic viral hepatitis C | Abstract similar documents |
| R. A. Yakhina, I. A. Lakman, D. A. Valishin, R. Kh. Bakhitova | ||
| "... Актуальность. Распространение хронического вирусного гепатита С (ХВГС) среди населения влечет за ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
| R. I. Yagudina, M. M. Murashko | ||
| "... пациентов использованы для оценки эффективности. Коэффициенты «затраты-эффективность» составили 440 759 руб ..." | ||
| Vol 6, No 1 (2013) | PHARMACOECONOMIC STUDY OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| "... составило 122.687 руб. против 3.646.833 руб. и 551.150 руб. соответственно. Таким образом, с точки зрения ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... добавлении к терапии метформином лираглутида составляет 1 348368 руб. и 1 807359 руб. при использовании ..." | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
| A. G. Tolkushin, N. L. Pogudina | ||
| "... затрат составила примерно 8,84 млн руб. и 17,72 млн руб. (из них 4,05 млн руб. и 5,58 млн руб. – прямые ..." | ||
| Vol 14, No 1 (2021) | Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District | Abstract similar documents |
| M. S. Soboleva, E. E. Loskutova | ||
| "... ценовом диапазоне 100–500 руб. пользуются комбинации: атенолол+хорталидон и бисопролол+амлодипин. В группе ..." | ||
| Vol 10, No 3 (2017) | Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia | Abstract similar documents |
| E. V. Ivanova, K. Z. Bachtiyarova | ||
| "... за год теряет 428 222 026,35 руб., при этом основную долю составляют прямые медицинские затраты, из ..." | ||
| Vol 18, No 2 (2025) | Population consumption of antihypertensive and lipid-lowering drugs in the Russian Federation (SPARDEC) | Abstract similar documents |
| Zh. D. Kobalava, I. K. Petrukhina, P. A. Lebedev, P. R. Blinkova, T. K. Ryazanova, E. P. Gladunova, E. V. Paranina | ||
| "... дозы (англ. defined daily dose, DDD) для диуретиков – 2,8 руб., для блокаторов кальциевых каналов – 3 ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... медицинские затраты на курс CP/EP + ATZ (2 310 546,07 руб.) были значительно ниже, чем на курс CP/EP + Durv (4 ..." | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| "... на лечение одного больного раком молочной железы с учетом схемы 6DAC составит 1 198 300 руб. и 1 371 ..." | ||
| Vol 5, No 3 (2012) | CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE | Abstract similar documents |
| E. E. Arinina, M. A. Rashyd | ||
| "... ® на Левемир® /НовоРапид®, которые составили 21774 руб. на одного пациента в год, а предотвращенные ..." | ||
| Vol 8, No 2 (2015) | CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER | Abstract similar documents |
| Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov | ||
| "... период лечения пяти внешних центральных венозных катетеров необходимо затратить 227250000 руб., а на ..." | ||
| Vol 8, No 2 (2015) | PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS | Abstract similar documents |
| Anton Alexandrovich Kasatkin | ||
| "... пациентов с тяжестью травмы 31 балл и составила 11000 и 5600 руб., соответственно. Затраты на лечение ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... . руб. / месяц сохраненной жизни против 136 тыс. руб./месяц для цетуксимаба и 310 тыс. руб. / месяц для ..." | ||
| Vol 8, No 4 (2015) | THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA | Abstract similar documents |
| K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva | ||
| "... 41,14 руб. соответственно. Стоимость одного предотвращенного случая НЭ благодаря вскармливанию ГМ ..." | ||
| Vol 17, No 2 (2024) | Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children | Abstract similar documents |
| A. S. Kolbin, A. R. Kasimova | ||
| "... здравоохранения и государства на 1 пациента с ОРЗ составляют 42 472 руб. при неосложненном течении и 70 649 руб ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... курс ланреотида на 2,5 года составили 1 466 669,49 руб. на 1 пациента с акромегалией по сравнению с 908 ..." | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION | Abstract similar documents |
| A. Yu. Kulikov, I. Yu. Zinchuk | ||
| "... Це- раксон в фармакотерапии ОНМК, обусловленное снижением суммы прямых затрат на 22 311 руб. и 21 345 ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic | Abstract similar documents |
| Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham | ||
| "... ., Швейцария) – 66 492,10 руб. и Исентресс® (ралтегравир; Merck Sharp & Dohme, Нидерланды) – 31 634,60 руб., а ..." | ||
| Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... ,6% по сравнению с ибрутинибом. Так, в 1-й год затраты на акалабрутиниб составили 3 546 237,60 руб., на ..." | ||
| Vol 16, No 1 (2023) | Efficiency of Levilimab in patients with moderate and severe COVID-19 | Abstract similar documents |
| Yu. M. Gomon, V. V. Strizheletsky, I. G. Ivanov, Yu. E. Balykina, M. V. Ermolyev, A. S. Kolbin, M. V. Livshits, T. A. Usmanova, A. M. Fakhrutdinova, Yu. S. Konstantinova, A. P. Gubanov | ||
| "... ,30 руб., с тяжелым течением – 91 285,85 руб. Расчетные показатели стоимости дополнительной эффективности ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| "... пациента со средней массой тела 88,3 кг и исходным уровнем гемоглобина 100 г/л составили 13 043 руб. для ..." | ||
| Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
| I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
| "... дельта 132 123,99 руб., фоллитропина альфа – 133 392,19 руб. Суммарные затраты на три цикла составили при ..." | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... % против 34,8% соответственно, р=0,031). Стоимость курса цефтазидим+авибактам составила 228,3 тыс. руб ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| "... потратить на 463 805 руб., или на 24,80% меньше, чем при использовании реслизумаба, и на 382 640 руб., или ..." | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings | Abstract similar documents |
| M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin | ||
| "... составили 0,99 млн руб. против 1,17 млн руб. в год на одного пациента. Таким образом, применение ..." | ||
| Vol 14, No 2 (2021) | Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation | Abstract similar documents |
| D. G. Shchurov, V. S. Dombrovskiy | ||
| "... 112 120 руб. на одного рожденного ребенка и 2519 руб. на один сохраненный год жизни. Наибольшие ..." | ||
| 1 - 50 of 121 Items | 1 2 3 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
